Eva Colas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4520990/publications.pdf

Version: 2024-02-01

57	6,001	172207	143772
papers	citations	29	57
		h-index	g-index

59	59	59	11548
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biological properties of extracellular vesicles and their physiological functions. Journal of Extracellular Vesicles, 2015, 4, 27066.	5.5	3,973
2	Molecular markers of endometrial carcinoma detected in uterine aspirates. International Journal of Cancer, 2011, 129, 2435-2444.	2.3	105
3	The EMT signaling pathways in endometrial carcinoma. Clinical and Translational Oncology, 2012, 14, 715-720.	1.2	95
4	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer, 2014, 13, 223.	7.9	88
5	L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. British Journal of Cancer, 2016, 115, 716-724.	2.9	76
6	Enabling Metabolomics Based Biomarker Discovery Studies Using Molecular Phenotyping of Exosome-Like Vesicles. PLoS ONE, 2016, 11, e0151339.	1.1	70
7	Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 1900.	1.0	67
8	Exosome-like vesicles in uterine aspirates: a comparison of ultracentrifugation-based isolation protocols. Journal of Translational Medicine, 2016, 14, 180.	1.8	64
9	PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate, 2010, 70, 1760-1767.	1.2	63
10	Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. International Journal of Cancer, 2018, 142, 1230-1243.	2.3	59
11	ERM/ETV5 Up-regulation Plays a Role during Myometrial Infiltration through Matrix Metalloproteinase-2 Activation in Endometrial Cancer. Cancer Research, 2007, 67, 6753-6759.	0.4	57
12	The Present and Future of Prostate Cancer Urine Biomarkers. International Journal of Molecular Sciences, 2013, 14, 12620-12649.	1.8	56
13	Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease. Molecular and Cellular Endocrinology, 2012, 358, 244-255.	1.6	54
14	Endometrial Carcinoma: Specific Targeted Pathways. Advances in Experimental Medicine and Biology, 2017, 943, 149-207.	0.8	53
15	Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. Carcinogenesis, 2009, 30, 1288-1297.	1.3	50
16	ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. International Journal of Cancer, 2012, 130, 1532-1543.	2.3	50
17	Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment. Clinical Cancer Research, 2017, 23, 6458-6467.	3.2	50
18	An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis. International Journal of Cancer, 2009, 125, 257-263.	2.3	44

#	Article	IF	Citations
19	A Threeâ€Gene panel on urine increases PSA specificity in the detection of prostate cancer. Prostate, 2011, 71, 1736-1745.	1.2	43
20	Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. International Journal of Gynecological Cancer, 2018, 28, 514-523.	1.2	43
21	Activated leukocyte cell adhesion molecule (<scp>ALCAM</scp>) is a marker of recurrence and promotes cell migration, invasion, and metastasis in earlyâ€stage endometrioid endometrial cancer. Journal of Pathology, 2017, 241, 475-487.	2.1	42
22	Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive Techniques. Journal of Minimally Invasive Gynecology, 2019, 26, 492-500.	0.3	42
23	High-Risk Endometrial Carcinoma Profiling Identifies TGF-Î²1 as a Key Factor in the Initiation of Tumor Invasion. Molecular Cancer Therapeutics, 2011, 10, 1357-1366.	1.9	41
24	Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion. Clinical and Experimental Metastasis, 2015, 32, 467-478.	1.7	40
25	Annexinâ€A2 as predictor biomarker of recurrent disease in endometrial cancer. International Journal of Cancer, 2015, 136, 1863-1873.	2.3	39
26	Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers. Modern Pathology, 2017, 30, 134-145.	2.9	36
27	Patient-Derived Xenograft Models for Endometrial Cancer Research. International Journal of Molecular Sciences, 2018, 19, 2431.	1.8	32
28	EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer. Scientific Reports, 2019, 9, 15057.	1.6	31
29	MicroRNAs as prognostic markers in ovarian cancer. Molecular and Cellular Endocrinology, 2014, 390, 73-84.	1.6	30
30	Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomasâ€"an ENITEC Group Initiative. Clinical Cancer Research, 2017, 23, 1274-1285.	3.2	30
31	Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma. International Journal of Cancer, 2017, 140, 1551-1563.	2.3	30
32	Metabolomic and Lipidomic Profiling Identifies The Role of the RNA Editing Pathway in Endometrial Carcinogenesis. Scientific Reports, 2017, 7, 8803.	1.6	30
33	EV-associated miRNAs from peritoneal lavage as potential diagnostic biomarkers in colorectal cancer. Journal of Translational Medicine, 2019, 17, 208.	1.8	30
34	Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer. Gynecologic Oncology, 2019, 153, 425-435.	0.6	30
35	Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer. Cancers, 2019, 11, 2000.	1.7	30
36	EV-Associated miRNAs from Peritoneal Lavage are a Source of Biomarkers in Endometrial Cancer. Cancers, 2019, 11, 839.	1.7	27

#	Article	IF	Citations
37	Generation and characterization of orthotopic murine models for endometrial cancer. Clinical and Experimental Metastasis, 2012, 29, 217-227.	1.7	26
38	Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Medicine, 2020, 17, e1003111.	3.9	25
39	Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples. Oncotarget, 2016, 7, 53102-53115.	0.8	24
40	Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer. Journal of Clinical Medicine, 2020, 9, 585.	1.0	23
41	Subtractive Proteomic Approach to the Endometrial Carcinoma Invasion Front. Journal of Proteome Research, 2009, 8, 4676-4684.	1.8	22
42	The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. Human Pathology, 2021, 109, 80-91.	1.1	22
43	Advances in endometrial cancer protein biomarkers for use in the clinic. Expert Review of Proteomics, 2018, 15, 81-99.	1.3	20
44	Metabotyping human endometrioid endometrial adenocarcinoma reveals an implication of endocannabinoid metabolism. Oncotarget, 2016, 7, 52364-52374.	0.8	17
45	Molecular diagnosis of endometrial cancer from uterine aspirates. International Journal of Cancer, 2013, 133, 2383-2391.	2.3	15
46	FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-Î²1 and NF-ÎºB Pathways. Frontiers in Oncology, 2019, 9, 1306.	1.3	15
47	Molecular Markers for Prostate Cancer in Formalin-Fixed Paraffin-Embedded Tissues. BioMed Research International, 2013, 2013, 1-15.	0.9	12
48	Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer. Cancers, 2020, 12, 2751.	1.7	12
49	ALCAM shedding at the invasive front of the tumor is a marker of myometrial infiltration and promotes invasion in endometrioid endometrial cancer. Oncotarget, 2018, 9, 16648-16664.	0.8	11
50	Poor outcome in hypoxic endometrial carcinoma is related to vascular density. British Journal of Cancer, 2019, 120, 1037-1044.	2.9	10
51	Identification of early stage recurrence endometrial cancer biomarkers using bioinformatics tools. Oncology Reports, 2020, 44, 873-886.	1.2	10
52	Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression. Oncogene, 2022, 41, 1835-1850.	2.6	9
53	In silico Approach for Validating and Unveiling New Applications for Prognostic Biomarkers of Endometrial Cancer. Cancers, 2021, 13, 5052.	1.7	8
54	Coexistence of homologous-type cervical carcinosarcoma with endometrioid-type G1 endometrial cancer: a case report with an immunohistochemical study. International Journal of Clinical and Experimental Pathology, 2014, 7, 7191-5.	0.5	6

#	Article	IF	Citations
55	Genomic Validation of Endometrial Cancer Patient-Derived Xenograft Models as a Preclinical Tool. International Journal of Molecular Sciences, 2022, 23, 6266.	1.8	6
56	Clinical management of early-stage cervical cancer: The role of sentinel lymph node biopsy in tumors â‰¥2â€¯cm. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 241, 30-34.	0.5	5
57	Modeling ANXA2-overexpressing circulating tumor cells homing and high throughput screening for metastasis impairment in endometrial carcinomas. Biomedicine and Pharmacotherapy, 2021, 140, 111744.	2.5	2